Алексеев Б.Я., Каприн А.Д., Матвеев В.Б., Нюшко К.М. Клинические рекомендации по диагностике и лечению рака предстательной железы. М., 2014. 44 с. Доступно по:http://oncology-association.ru/docs/recomend/may2015/39vz-rek.pdf
American Cancer Society. Cancer Facts & Figures. 2017. Available at:https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.
Vickers A., Cronin A., Roobol M. et al. Reducing unnecessary biopsy during prostate cancer screening using a fourkallikrein panel: an independent replication. J Clin Oncol 2010;28(15):2493–8.
DOI: 10.1200/JCO.2009.24.1968
Куплевацкий В.И., Черкашин М.А., Рощин Д.А. и др. Биопсия предстательной железы под контролем магнитно-резонансной томографии. Вестник рентгенологии и радиологии 2016;97(1):48–55.
DOI: 10.20862/0042-4676-2016-97-1-48-55.
Архипова О.Е., Черногубова Е.А., Куролап С.А., Епринцев С.А. Эпидемиология рака предстательной железы в Воронежской области: пространственно-временная статистика. Вестник урологии 2016;(4):45–55.
DOI: 10.1234/XXXX-XXXX-2016-4-45-55.
Gathirua-Mwangi W.G., Zhang J. Dietary factors and risk for advanced prostate cancer. Eur J Cancer Prev 2014;23(2):96–109.
DOI: 10.1097/CEJ.0b013e3283647394
Schröder F.H., Hugosson J., Roobol M.J. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384(9959):2027–35.
DOI: 10.1016/S0140-6736(14)60525-0
Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostatespecific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22): 2239–46.
DOI: 10.1056/NEJMoa031918
Kretschmer A., Tilki D. Biomarkers in prostate cancer – current clinical utility and future perspectives. Crit Rev Oncol Hematol 2017;120:180–93.
DOI: 10.1016/j.critrevonc.2017.11.007
Stamey T.A., Yang N., Hay A.R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909–16.
DOI: 10.1056/NEJM198710083171501
Semjonow A., Brandt B., Oberpenning F. et al. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 1996;7:3–16
Parekh D.J., Punnen S., Sjoberg D.D. et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol 2015;68(3):464–70.
DOI: 10.1016/j. eururo.2014.10.021
Salami S.S., Schmidt F., Laxman B. et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2013;31(5):566–71.
DOI: 10.1016/j.urolonc.2011.04.001
Пушкарь Д.Ю., Говоров А.В., Сидоренков А.В. и др. Ранняя диагностика рака предстательной железы: методические рекомендации № 19. М.: АБВ-пресс, 2015. 54 с.
Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA, 1997. 277(18): p. 1452–5.
Catalona W.J., Partin A.W., Slawin K.M. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279(19):1542–7
Catalona W.J., Smith D.S., Wolfert R.L. et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274(15):1214–20
Filella X., Gimenez N. Evaluation ofproPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51(4):729–39.
DOI: 10.1515/cclm-2012-0410
Ito K., Miyakubo M., Sekine Y. et al. Diagnostic significance ofpro-PSA and prostate dimension-adjusted PSArelated indices in men with total PSA in the 2.0–10.0 ng/mL range. World J Urol 2013;31(2):305–11.
DOI: 10.1007/s00345-012-0927-9
Tosoian J.J., Druskin S.C., Andreas D. et al. Prostate Health Index density improves detection of clinically significant prostate cancer. BJU Int 2017;120(6):793–8.
DOI: 10.1111/bju.13762
Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71(4):618–29.
DOI: 10.1016/j.eururo.2016.08.003
NCCN Clinical Practice Guidelines in Oncology. Available at:https://www.nccn.org/professionals/physician_gls/default.aspx.
Leyten G.H., Hessels D., Smit F.P. et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res 2015;21(13):3061–70.
DOI: 10.1158/107800432.CCR-140-3334
Van Neste L., Hendriks R.J., Dijkstra S. et al. Detection of high-grade prostate cancer using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol 2016;70(5):740–8.
DOI: 10.1016/j.eururo.2016.04.012
Chan T.A., Glockner S., Yi J.M. et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 2008;5(5):e114.
DOI: 10.1371/journal.pmed.0050114
Van Neste L., Herman J.G., Otto G. et al. The epigenetic promise for prostate cancer diagnosis. Prostate 2012;72(11):1248–61.
DOI: 10.1002/pros.22459
Henrique R., Jerόnimo C., Teixeira M.R. et al. Epigenetic heterogeneity of highgrade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006;4(1):1–8.
DOI: 10.1158/1541-7786.MCR-05-0113
Henrique R., Jerόnimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004;46(5):660–9.
DOI: 10.1016/j.eururo.2004.06.014
Woodson K., O’Reilly K.J., Hanson J.C. et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol 2008;179(2):508–11.
DOI: 10.1016/j.juro.2007.09.073
Gurioli G., Martignano F., Salvi S. et al. GSTP1 methylation in cancer: a liquid biopsy biomarker? Clin Chem Lab Med 2018 Jan 6.
DOI: 10.1515/cclm-2017-0703
Fradet Y., Saad F., Aprikian A. et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64(2):311–5.
DOI: 10.1016/j.urology.2004.03.052
Hansen J., Auprich M., Ahyai S.A. et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 2013;63(2):201–9.
DOI: 10.1016/j.eururo.2012.07.030
De la Taille A., Irani J., Graefen M. et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011;185(6):2119–25.
DOI: 10.1016/j.juro.2011.01.075
Tomlins S.A., Day J.R., Lonigro R.J. et al. Urine TMPRSS2: ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol 2016;70(1):45–53.
DOI: 10.1016/j.eururo.2015.04.039
Nilsson J., Skog J., Nordstrand A. et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009;100(10):1603–7
Donovan M.J., Noerholm M., Bentink S. et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis 2015;18(4):370–5.
DOI: 10.1038/pcan.2015.40
McKiernan J., Donovan M.J., O»Neill V. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol 2016;2(7):882–9.
DOI: 10.1001/jamaoncol.2016.0097